Evidence map›Paper›PMID 39565570›Full record

Trial reportLa Radiologia medica2025

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.

Matthew S Robertson, Yating Wang, SuChun Cheng, Hyesun Park, Shahar Glomski, Lauren C Harshman, Amanda Pace, Jacqueline Kilar, Meredith Flynn, Lauren Gilbert and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03093428 (A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03093428 phase2completednot on this map

A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2017 to 2025Enrolled45ConditionsProstate CancerArmsRadium-223, Pembrolizumab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew S RobertsonDepartment of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA. mrobertson@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-1291-4654
Yating WangDivision of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
SuChun ChengDivision of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Hyesun ParkDepartment of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA.
Shahar GlomskiDepartment of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA.
Lauren C HarshmanLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amanda PaceLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacqueline KilarLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Meredith FlynnLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lauren GilbertDepartment of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA.
Atish D ChoudhuryLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Heather JaceneDepartment of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this study is to demonstrate the consistency and reproducibility of quantitative SPECT/CT by evaluating the maximum SUV (SUV MATERIAL AND

methodsThis prospective imaging sub-study was performed as part of a phase 2 clinical trial of patients with metastatic castration-resistant prostate cancer (mCRPC) randomized to the combination of pembrolizumab plus radium-223 or to radium-223 alone (NCT03093428). The maximum standardized uptake value (SUV

resultsTwenty-one patients were enrolled on the imaging sub-study of which 15 had paired baseline S

conclusionQuantitative SPECT/CT provides consistent and objective imaging parameters, which can help monitor tumor burden. The median SUVmax of metastasis at baseline was roughly 7.2-fold higher than normal bone. Quantitative SPECT/CT may help visualize the early osteoblastic treatment response in prostate cancer patients treated with radium-223 alone or combined with pembrolizumab.

Indexed as

Antibodies, Monoclonal, HumanizedBone NeoplasmsProstatic Neoplasms, Castration-ResistantRadiumSingle Photon Emission Computed Tomography Computed TomographyAgedAged, 80 and overAntineoplastic Agents, ImmunologicalHumansMaleMiddle AgedProspective StudiesReproducibility of ResultsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabRadiumRadium-223QuantitativeRadiotherapySPECT/CT

Identifiers

PMID39565570

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.